These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 17654511

  • 1. Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer.
    Leonetti C, Biroccio A, D'Angelo C, Semple SC, Scarsella M, Zupi G.
    Prostate; 2007 Sep 15; 67(13):1475-85. PubMed ID: 17654511
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
    Zupi G, Scarsella M, Semple SC, Mottolese M, Natali PG, Leonetti C.
    Clin Cancer Res; 2005 Mar 01; 11(5):1990-8. PubMed ID: 15756025
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs.
    Dandekar DS, Lokeshwar BL.
    Clin Cancer Res; 2004 Dec 01; 10(23):8037-47. PubMed ID: 15585639
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.
    Citro G, D'Agnano I, Leonetti C, Perini R, Bucci B, Zon G, Calabretta B, Zupi G.
    Cancer Res; 1998 Jan 15; 58(2):283-9. PubMed ID: 9443406
    [Abstract] [Full Text] [Related]

  • 9. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW, Kuhn J, Schwartz G, Patnaik A, Hammond LA, Thompson I, Fingert H, Bushnell D, Malik S, Kreisberg J, Izbicka E, Smetzer L, Rowinsky EK.
    Clin Cancer Res; 2004 Aug 01; 10(15):5048-57. PubMed ID: 15297406
    [Abstract] [Full Text] [Related]

  • 10. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
    Sowery RD, Hadaschik BA, So AI, Zoubeidi A, Fazli L, Hurtado-Coll A, Gleave ME.
    BJU Int; 2008 Aug 01; 102(3):389-97. PubMed ID: 18336596
    [Abstract] [Full Text] [Related]

  • 11. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice.
    Tang Y, Khan MA, Goloubeva O, Lee DI, Jelovac D, Brodie AM, Hussain A.
    Clin Cancer Res; 2006 Jan 01; 12(1):169-74. PubMed ID: 16397039
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
    Thomas SM, Ogagan MJ, Freilino ML, Strychor S, Walsh DR, Gooding WE, Grandis JR, Zamboni WC.
    Mol Pharmacol; 2008 Mar 01; 73(3):627-38. PubMed ID: 18025070
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells.
    Devi GR, Oldenkamp JR, London CA, Iversen PL.
    Prostate; 2002 Nov 01; 53(3):200-10. PubMed ID: 12386920
    [Abstract] [Full Text] [Related]

  • 17. Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft.
    Spugnini EP, Biroccio A, De Mori R, Scarsella M, D'Angelo C, Baldi A, Leonetti C.
    J Transl Med; 2011 Jul 28; 9():125. PubMed ID: 21798045
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans.
    Iversen PL, Arora V, Acker AJ, Mason DH, Devi GR.
    Clin Cancer Res; 2003 Jul 28; 9(7):2510-9. PubMed ID: 12855625
    [Abstract] [Full Text] [Related]

  • 19. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
    Miyake H, Chi KN, Gleave ME.
    Clin Cancer Res; 2000 May 28; 6(5):1655-63. PubMed ID: 10815883
    [Abstract] [Full Text] [Related]

  • 20. Tumor regression by combination antisense therapy against Plk1 and Bcl-2.
    Elez R, Piiper A, Kronenberger B, Kock M, Brendel M, Hermann E, Pliquett U, Neumann E, Zeuzem S.
    Oncogene; 2003 Jan 09; 22(1):69-80. PubMed ID: 12527909
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.